2004
Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1
Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research 2004, 64: 7355-7360. PMID: 15492256, DOI: 10.1158/0008-5472.can-04-0154.Peer-Reviewed Original ResearchConceptsTSU-Pr1Cell line TSU-Pr1BMP-RIITumor growthBladder transitional cell carcinoma cellsHuman bladder cancer cell linesCell linesTransitional cell carcinoma cellsBladder cancer cell linesBone morphogenetic protein receptor type II (BMPR2) expressionBone morphogenetic proteinTSU-Pr1 cellsBladder TCC tissuesGrowth inhibitory effectsCancer cell linesBladder specimensType II expressionBladder TCCTumor gradeTransitional epitheliumClinical observationsTCC tissuesMalignant cellsSignificant associationBMP-RIALoss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchMeSH KeywordsBone Morphogenetic Protein Receptors, Type IIDisease ProgressionGene Expression Regulation, NeoplasticHumansMaleNeoplasm StagingProstateProstatic NeoplasmsProtein Serine-Threonine KinasesTumor Cells, CulturedConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic value
2003
Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.
Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. PMID: 14676131.Peer-Reviewed Original ResearchBlotting, NorthernBone Morphogenetic Protein 6Bone Morphogenetic Protein Receptors, Type IIBone Morphogenetic ProteinsCarcinoma, Renal CellDown-RegulationHumansImmunoblottingImmunoenzyme TechniquesKidney NeoplasmsProtein Serine-Threonine KinasesReceptors, Cell SurfaceReverse Transcriptase Polymerase Chain ReactionTransforming Growth Factor betaTumor Cells, Cultured
2000
Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor
Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor. The Prostate 2000, 43: 118-124. PMID: 10754527, DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsApoptosisGenes, DominantGenomeImmunohistochemistryMaleMiceMice, TransgenicOrgan SizePromoter Regions, GeneticProstateProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptors, AndrogenReceptors, Transforming Growth Factor betaTestosteroneConceptsVentral prostateEpithelial cellsAnimal prostatesDominant negative receptorTransgenic miceNegative receptorProstate-specific promotersProstatic epithelial cellsTransgenic mouse systemTGF-beta resultsSerum levelsTGF-beta signalingProstate growthProstatic growthNormal prostateAndrogenic statusProstateProximal ductExperimental modelLoss of apoptosisInhibitory effectMouse systemSignificant differencesAbnormal morphologyLoss of sensitivity
1998
The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP
Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IDihydrotestosteroneGene ExpressionHumansMaleProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRNA, MessengerSensitivity and SpecificitySignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsHuman prostate cancer cell linesCompetitive quantitative RT-PCRProstate cancer cell linesType II receptorLNCaP cellsII receptorsWestern blot analysisQuantitative RT-PCRCancer cell linesTGF-beta signalingALK-5RT-PCRALK-1Androgen-responsive human prostate cancer cell lineGrowth factor-β receptor type IType II receptor mRNAReceptor type IConcentrations of dihydrotestosteroneTGF-β1 signalingCell linesBlot analysisType INM dihydrotestosteroneReceptor mRNADihydrotestosterone
1996
Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. PMID: 9816295.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsAntibody SpecificityHumansImmunohistochemistryMaleProstatic NeoplasmsProtein Serine-Threonine KinasesRabbitsReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTumor Cells, CulturedConceptsType II receptorHuman prostate cancer tissuesProstate cancer tissuesII receptorsProstate cancer cellsLoss of expressionTumor gradeTGF-beta receptorsCancer tissuesProstate tissueTGF-beta1 type IProstate cancer cell growthMalignant human prostate tissueType ICancer cellsHuman prostate cancer cellsGrowth factor-beta type IProstate cancer casesHuman prostate cancerBenign prostate tissueCancer cell growthHuman prostate tissueTGF-beta type IGrowth factor beta1Benign human prostateModulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone. Experimental Cell Research 1996, 222: 103-110. PMID: 8549651, DOI: 10.1006/excr.1996.0013.Peer-Reviewed Original ResearchMeSH KeywordsBinding, CompetitiveCell CountCell DivisionDihydrotestosteroneDNA, NeoplasmHumansMalePromoter Regions, GeneticProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaTranscriptional ActivationTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta receptor type IILNCaP cellsReceptor type IIAndrogen-responsive prostate cancerCharcoal-stripped fetal bovine serumEffect of dihydrotestosteroneGrowth factor-β1Type II TGF-β receptorProstate cancer cellsGrowth inhibitory effectsTGF-β receptorWestern blot analysisDHT concentrationsPresent studyType IIModulation of sensitivityProstate cancerAndrogenic conditionsFactor-β1DihydrotestosteronePotential physiological regulatorsInhibitory effectGene transcriptional activityCancer cellsPhysiological regulator